Buy Glaxo and Cipla: Sandeep Wagle
We are having a target of somewhere around 335 in Cipla which is around 5% to 7% from the current levels.
By 
|
| Sandeep Wagle, Founder & MD, APTART Technical Advisory Services in an interview with ET Now talks about Cipla.
What do you make of these two -- Cipla and GlaxoSmithKline? What are the targets that we need to look out for?
Well the breakout has come yesterday and what we are seeing today is possibly a pullback or a consolidation. We are having a target of somewhere around 335 in Cipla which is around 5% to 7% from the current levels, can be bought for a play of around a week or so and we have a buy in Glaxo with the target of 2160 can be bought at 2070-2050 range with a stop loss of 2035.
What do you make of these two -- Cipla and GlaxoSmithKline? What are the targets that we need to look out for?
Well the breakout has come yesterday and what we are seeing today is possibly a pullback or a consolidation. We are having a target of somewhere around 335 in Cipla which is around 5% to 7% from the current levels, can be bought for a play of around a week or so and we have a buy in Glaxo with the target of 2160 can be bought at 2070-2050 range with a stop loss of 2035.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
